ONCOINVENT ASA (ONCIN.OL) Stock Price, Forecast & Analysis
Europe - OSL:ONCIN - NO0013251173 - Common Stock
ONCIN.OL Key Statistics, Chart & Performance
The current stock price of ONCIN.OL is 1.214 NOK.
ONCIN.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.48 | 212.54B | ||
| SAN.PA | SANOFI | 11.24 | 208.13B | ||
| SNW.DE | SANOFI | 11.24 | 208.11B | ||
| 1MRK.MI | MERCK KGAA | 13.35 | 49.41B | ||
| MRK.DE | MERCK KGAA | 12.86 | 47.59B | ||
| UCB.BR | UCB SA | 35.31 | 44.10B | ||
| 1BAYN.MI | BAYER AG-REG | 5.28 | 26.00B | ||
| BAYN.DE | BAYER AG-REG | 5.2 | 25.60B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.24 | 10.40B | ||
| IPN.PA | IPSEN | 12.05 | 10.38B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 97.84 | 9.06B | ||
| VIRP.PA | VIRBAC SA | 19.9 | 2.89B |
Related stock screener links
About ONCIN.OL
Company Profile
Oncoinvent ASA engages in the development of cancer treatment products. The company is headquartered in Oslo, Oslo and currently employs 34 full-time employees. The company went IPO on 2024-12-13. The firm is engaged in the development of alpha-emitting radiotherapeutics that provide better treatment options to cancer patients. The firm offers Radspherin, which is alpha-emitting radioactive microsphere therapy designed for the treatment of metastatic cancers in body cavities. The product candidate is a suspension of inorganic microspheres labelled with an alpha-emitting radioisotope for local administration. More specifically it consists of with calcium carbonate micro particles labelled with the radioisotope Radium-224d. The therapeutic goal is to treat residual micro metastases remaining after surgery in intracavitary surfaces and liquid without subjecting deeper regions of organs and tissues to harmful radiation doses.
Company Info
ONCOINVENT ASA
Gullhaugveien 7
Oslo OSLO NO
Employees: 34
Phone: 4722183305
ONCOINVENT ASA / ONCIN.OL FAQ
What does ONCOINVENT ASA do?
Oncoinvent ASA engages in the development of cancer treatment products. The company is headquartered in Oslo, Oslo and currently employs 34 full-time employees. The company went IPO on 2024-12-13. The firm is engaged in the development of alpha-emitting radiotherapeutics that provide better treatment options to cancer patients. The firm offers Radspherin, which is alpha-emitting radioactive microsphere therapy designed for the treatment of metastatic cancers in body cavities. The product candidate is a suspension of inorganic microspheres labelled with an alpha-emitting radioisotope for local administration. More specifically it consists of with calcium carbonate micro particles labelled with the radioisotope Radium-224d. The therapeutic goal is to treat residual micro metastases remaining after surgery in intracavitary surfaces and liquid without subjecting deeper regions of organs and tissues to harmful radiation doses.
Can you provide the latest stock price for ONCOINVENT ASA?
The current stock price of ONCIN.OL is 1.214 NOK. The price decreased by -3.19% in the last trading session.
Does ONCIN stock pay dividends?
ONCIN.OL does not pay a dividend.
How is the ChartMill rating for ONCOINVENT ASA?
ONCIN.OL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
When does ONCOINVENT ASA (ONCIN.OL) report earnings?
ONCOINVENT ASA (ONCIN.OL) will report earnings on 2025-11-11.
What is the ownership structure of ONCOINVENT ASA (ONCIN.OL)?
You can find the ownership structure of ONCOINVENT ASA (ONCIN.OL) on the Ownership tab.
ONCIN.OL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ONCIN.OL.
ONCIN.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ONCIN.OL. No worries on liquidiy or solvency for ONCIN.OL as it has an excellent financial health rating, but there are worries on the profitability.
ONCIN.OL Financial Highlights
Over the last trailing twelve months ONCIN.OL reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS increased by 70.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -160.55% | ||
| ROE | -207.87% | ||
| Debt/Equity | 0 |
ONCIN.OL Forecast & Estimates
9 analysts have analysed ONCIN.OL and the average price target is 2.75 NOK. This implies a price increase of 126.85% is expected in the next year compared to the current price of 1.214.
For the next year, analysts expect an EPS growth of 65.94% and a revenue growth 6400% for ONCIN.OL